

MERCK'S COMMITMENT TO HEPATITIS C

An estimated

2.7-3.9

MILLION AMERICANS

are living with chronic hepatitis C virus (HCV) infection, a disease that can lead to long-term health consequences like liver failure or liver cancer. For more than 30 years, Merck has been at the forefront of the response to chronic HCV and our team continues to work tirelessly to advance scientific knowledge of this significant public health issue.

MERCK IS
PROUD OF ITS
CONTRIBUTIONS
TOWARD
ADVANCING
THE SCIENCE
OF CHRONIC HCV.

In the past decade, Merck's clinical development programs in chronic HCV infection have:



Enrolled
approximately

10,000
PARTICIPANTS



>135
CLINICAL TRIALS
in approximately
40 countries

“

*What drives us to address the major public health issues today is the fact that we have the opportunity and the tools available to **advance scientific understanding.***

”

– DR. ELIAV BARR

Vice President, Clinical Research, Infectious Disease

Our pursuit of innovation will continue. As part of our longstanding leadership in infectious diseases, Merck is committed to broadening access to help make treatment an option for all patients infected with HCV. We will continue our collaborations with the scientific community, patient advocates, local governments and other stakeholders to accelerate our collective goal of addressing the burden of chronic HCV.

